CTLA4 and hepatocellular carcinoma: Targeting this signaling is important for cancer treatment, as anti-CTLA-4 monotherapy prevents its binding with B7 molecules, inhibiting the negative stimulatory signal and thus promoting T-cell activation, providing persistent immune restoration and a prolonged survival rate in HCC patients [45].